



HAL
open science

Oncostatin M up-regulates the ER chaperone Grp78/BiP in liver cells

Stefan Vollmer, Claude Haan, Iris Behrmann

► **To cite this version:**

Stefan Vollmer, Claude Haan, Iris Behrmann. Oncostatin M up-regulates the ER chaperone Grp78/BiP in liver cells. *Biochemical Pharmacology*, 2010, 80 (12), pp.2066. 10.1016/j.bcp.2010.07.015 . hal-00637152

HAL Id: hal-00637152

<https://hal.science/hal-00637152>

Submitted on 31 Oct 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Accepted Manuscript

Title: Oncostatin M up-regulates the ER chaperone Grp78/BiP in liver cells

Authors: Stefan Vollmer, Claude Haan, Iris Behrmann

PII: S0006-2952(10)00526-5
DOI: doi:10.1016/j.bcp.2010.07.015
Reference: BCP 10648

To appear in: *BCP*

Received date: 10-5-2010
Revised date: 2-7-2010
Accepted date: 8-7-2010

Please cite this article as: Vollmer S, Haan C, Behrmann I, Oncostatin M up-regulates the ER chaperone Grp78/BiP in liver cells, *Biochemical Pharmacology* (2010), doi:10.1016/j.bcp.2010.07.015

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



1
2
3
4 **Oncostatin M up-regulates the ER chaperone Grp78/BiP in liver cells**
5
6
7

8
9 Stefan Vollmer¹, Claude Haan^{1*}, and Iris Behrmann^{1*}
10
11

12
13
14 ¹ Life Sciences Research Unit -Signal Transduction Laboratory, University of Luxembourg,
15
16 162A, av. de la Faiencerie, 1511 Luxembourg, Luxembourg
17
18
19
20
21
22
23
24
25
26
27

28
29 * IB and CH share senior authorship
30
31
32

33
34 *Corresponding authors:*
35

36 Iris Behrmann
37

38 Fax +352 466644 6435, Tel. +352 466644 6740, e-mail: iris.behrmann@uni.lu
39
40

41 Claude Haan
42

43 Fax +352 466644 6435, Tel. +352 466644 6438, e-mail: claude.haan@uni.lu
44
45
46
47

48 *Keywords:*
49

50 cytokines; Oncostatin M; Grp78/BiP; cytokine signal transduction, Jak/STAT; MAP kinases
51
52
53
54

55 *Abbreviations:*
56

57 Erk, extracellular signal-regulated kinase; Grp, Glucose regulated protein; HIF, hypoxia-
58
59
60
61
62
63
64
65

1
2
3
4 inducible factor; IFN, interferon; IL, interleukin; Jak, Janus kinase; MAPK, mitogen activated
5
6
7 kinase; OSM, Oncostatin M; STAT, signal transducer and activator of transcription;
8
9

10
11 *Financial support:*

12
13
14 This work was supported by UL grant F1R-LSC-PUL-09HYST and by the FNR (AFR) grant
15
16 TR-PHD BFR08-040.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Abstract

OSM, a cytokine of the IL-6 type cytokine family, regulates inflammatory processes (acute phase, tissue remodeling, angiogenesis), cell differentiation and proliferation. Inflammation is discussed to favor carcinogenesis and the inflammatory cytokine OSM was lately described to upregulate HIF-1 α , whose upregulation is also observed in many cancers. In this study we demonstrate that OSM, and to a lesser degree by IL-6, induces the expression of Grp78/BiP, an ER chaperone associated with tumor development and poor prognosis in cancer. In contrast, IFN- γ or TNF- α had no effect on Grp78 expression. The up-regulation seems to be specific to liver cells, as it occurs in hepatocytes and hepatoma cells but not in prostate, melanoma, breast or kidney cells. OSM does not lead to up-regulation of Grp94, enhanced XBP-1 mRNA splicing or phosphorylation of eIF2 α , indicating that it is not associated to a general ER stress response. Analysis of the underlying mechanism showed that Grp78 is up-regulated by transcriptional processes which are to the greater part, though not completely, dependent on MEK/Erk activation.

Introduction

The family of interleukin (IL)-6-type cytokines includes IL-6, IL-11, oncostatin M (OSM), leukemia inhibitory factor (LIF), cardiotrophin 1 and ciliary neurotrophic factor (CNTF). All of these cytokines bind to membrane receptor complexes containing the signal transducing receptor chain gp130 (glycoprotein 130). OSM signals either via an OSMR/gp130 or a LIFR/gp130 receptor complex [1]. Upon binding of OSM to its receptor complex, Janus kinases (Jaks) become activated. These Jaks (mainly Jak1) phosphorylate certain tyrosine residues within the receptor chains leading to the formation of docking sites for signaling molecules with matching SH2 domains, like signal transducers and activators of transcription (STAT) or adaptor proteins for the mitogen-activated protein kinase pathway (MAPK) [2, 3]. STAT3 as well as the extracellular signal-regulated kinase (Erk) 1/2 and p38 are the major signaling cascades that are activated by OSM. OSM is a pleiotropic cytokine produced by various different cell types e.g. monocytes, macrophages and T cells. It is involved in cell differentiation, in proliferation, in inflammatory processes (e.g. acute phase response), in hematopoiesis and in angiogenesis [1, 2, 4]. In addition OSM functions in tissue remodeling and is an important factor for liver development and regeneration [5, 6] .

Grp78 (glucose regulated protein 78) was discovered in 1977 [7]. Its alternative name BiP (immunoglobulin heavy chain binding protein) originates from the identification of Grp78 as cofactor of the immunoglobulin assembly [8]. It belongs to the heat shock protein 70 kDA (Hsp70) family and is their most abundant member in the endoplasmic reticulum (ER) [9]. Furthermore, a cytosolic form of Grp78 has been reported [10]. There are also studies describing extracellular and cell surface-bound BiP [11, 12]. Like all Hsp70 family members,

1
2
3
4 Grp78 binds and hydrolyzes ATP, which controls its chaperoning function. Hsp70 proteins are
5
6 in an “open” configuration when ATP is bound. Via the substrate binding domain (SBD) of the
7
8 chaperone, hydrophobic oligopeptides within more or less unfolded polypeptides are recruited
9
10 to the folding complex. Binding of substrates to the SBD inhibits unproductive interactions of
11
12 the polypeptide and favors productive folding and assembly that occurs concomitant with
13
14 release from Hsp70 [13].
15
16
17

18
19 Besides its role in folding and assembly of newly synthesized proteins, Grp78 is a major
20
21 regulator of ER homeostasis. Sensing critical amounts of unfolded proteins, Grp78 can trigger
22
23 the unfolded protein response (UPR) via dissociation from its interaction partners PERK,
24
25 ATF6 and IRE1 α , which will subsequently lead to activation of ER stress responses involving
26
27 an induced expression of ER chaperones to increase the folding capacity of the ER [14].
28
29 Known inducers of ER stress such as tunicamycin (an inhibitor of N-linked glycosylation) and
30
31 thapsigargin (an inhibitor of the ER Ca²⁺-ATPase) result in a strong increase of Grp78
32
33 expression [15, 16]. In tumor cells Grp78 expression is associated with proliferation, survival,
34
35 and resistance against chemotherapeutics [17].
36
37
38
39

40
41 IL6-type cytokine signaling via gp130 has been associated with the development of
42
43 hepatocellular carcinoma [18, 19]. Not much is known about possible interactions between IL-
44
45 6-type cytokines and the ER chaperones Grp78 and Grp94. An increased expression of Grp78
46
47 or Grp94 induced by IL-6-type cytokines has not been shown previously. Chen et al. [20] could
48
49 show an increase of Grp78 in burn-injured mice. They speculate that this effect could be
50
51 mediated by IL-6 since this cytokine is also produced upon burn injury. OSM and IL-6 are
52
53 known are both inducer of the acute phase response, a process where large amounts of proteins
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 are produced and secreted by the liver [21, 22]. Thus, an increase of ER chaperone levels
5
6 would maybe be beneficial or even necessary for the acute phase response.
7
8

9 In this study we investigated whether inflammatory cytokines can induce the expression of
10
11 Grp78 or Grp94. Our results show that the expression of Grp78 but not of Grp94 can be
12
13 induced by OSM in hepatocytes/hepatoma cells and we analyze the underlying mechanism.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62

Material and methods

Cell culture and reagents

HepG2 hepatoma cells were maintained in DMEM/NUT-MIX-F12 medium (Lonza, Basel, Switzerland) supplemented with 10% fetal calf serum (PAA), 100 mg/L streptomycin, and 60 mg/L penicillin (Cytogen, Princeton, NJ, USA). The human hepatocyte cell line PH5CH8 [23] was kindly provided by Dr. Kato, Okayama. The human hepatoma cell line Huh-7 as well as HEK cells, the breast cancer cell line MCF-7 and DU-145 prostate cancer cells were cultured in DMEM medium (Lonza, Basel, Switzerland) supplemented with 10% fetal calf serum (PAA), 100 mg/L streptomycin, and 60 mg/L penicillin (Cytogen, Princeton, NJ, USA). The melanoma cell line FM55M1 and the human prostate cancer cell line PC-3 were cultured in RPMI medium (Lonza, Basel, Switzerland) supplemented with 10% fetal calf serum (PAA), 100 mg/L streptomycin, and 60 mg/L penicillin (Cytogen, Princeton, NJ, USA).

Cells were grown at 37°C in a water-saturated atmosphere at 5% CO₂. For glucose starvation the cells were cultured in glucose-free DMEM-Medium. HepG2 cells were transiently transfected using the TransIT LT1 reagent (Mirus, Madison, WI, USA) according to the manufacturer's recommendations. Stable knock-downs of STAT3 or HIF-1 α in HepG2 cells were generated using pGENEClip vectors encoding shRNA against STAT3 or HIF-1 α (SAB Biosciences, Frederick, MA, USA).

Human recombinant OSM, IL-6, IFN- γ and TNF- α were from Peprotech (Rocky Hill, NJ, USA). Actinomycin D, cycloheximide, tunicamycin, thapsigargin, Jak inhibitor I and U0126 were from Calbiochem (San Diego, CA, USA).

Western blot analysis and antibodies

1
2
3
4 Cells were lysed on the dish with lysis buffer containing 30 mM Tris/HCl pH6.7, 5% glycerol,
5
6 2.5% mercaptoethanol, 1% SDS. The lysates were further analyzed by SDS-PAGE and
7
8 Western blotting. All experiments were performed at least three times. A representative of
9
10 these independent biological experiments is shown. Quantification of Western blots was
11
12 performed using ImageJ software. Antibodies against HIF-1 α , phospho-STAT1, phospho-
13
14 STAT5, STAT1, STAT3 and FIN-13 were from BD Transduction Laboratories (San Diego,
15
16 CA, USA). Antibodies against Grp78, Grp94, phospho-STAT3, phospho-Erk1/2, phospho-p38,
17
18 p38, phospho-eIF2 α and eIF2 α were from Cell Signaling (Danvers, MA, USA). The
19
20 antibodies against Erk1/2 and STAT5 were purchased from Santa Cruz (Santa Cruz, CA,
21
22 USA). ECL signals were detected as described [24]. Before re-probing, blots were stripped as
23
24 described before [3].
25
26
27
28
29
30
31
32
33

34 ***Reporter gene assays***

35
36 HepG2 cells were transfected with 1 μ g of the β -galactosidase control plasmid (pCH110, GE
37
38 Healthcare, Piscataway, NJ, USA) and 1.5 μ g of the Grp78 promoter reporter gene construct
39
40 comprising 374 bp of the human Grp78 promoter [25] kindly provided by Dr. Kyoungsook
41
42 Park. 24 hours after transfection, the cells were treated with the different stimuli as described in
43
44 the figure legends. Cell lysis and luciferase assays were performed using the Promega
45
46 luciferase assay system (Promega, Madison, WI, USA). All experiments were performed at
47
48 least in triplicate and technical triplicates were also performed within one experiment.
49
50
51 Luciferase activity values were normalized to transfection efficiency monitored by the
52
53 cotransfected β -galactosidase expression vector. For all experiments the luciferase activity
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 values after OSM stimulation were additionally normalized to values from control
5
6 unstimulated cells.
7
8
9

10 11 12 ***Quantitative real-time PCR*** 13

14
15 Total RNA was extracted using the NucleoSpin RNA II Kit (Macherey Nagel, Düren,
16
17 Germany) according to the manufacturer's instruction with additional on-column DNase I
18
19 digestion. Quantity and purity of RNA samples was assessed using a NanoDrop ND1000
20
21 spectrophotometer. 500 ng of total RNA was reverse transcribed in a 10 µL reaction volume
22
23 containing 50 µM oligo(dT)₂₀ (Invitrogen, Carlsbad, CA, USA), 10 mM dNTPs (NEB,
24
25 Ipswich, MA, USA), 0.1M DTT (GE Healthcare, Piscataway, NJ, USA), 5x RT buffer (250
26
27 mM Tris-HCl pH=8.3, 375 mM KCl, 15 mM MgCl₂), 7.5 units MultiScribe Reverse
28
29 Transcriptase (Applied Biosystems, Carlsbad, CA, USA) and 3 units RNase Inhibitor (Applied
30
31 Biosystems, Carlsbad, CA, USA). Thermal cycling conditions included an initial denaturation
32
33 step of the RNA template and oligo(dT)₂₀ primer at 65°C for 5 min. Followed by the addition
34
35 of RT buffer, DTT and enzymes and incubation at 42°C for 1h. MultiScribe was heat-
36
37 inactivated at 85°C for 5 min. The cDNA was additionally treated with 2 units of RNase H
38
39 (NEB, Ipswich, MA, USA) at 37°C for 20 min. Quantitative real time PCR (qPCR) was carried
40
41 out on a CFX96 Real-Time PCR detection system (Bio-Rad Laboratories, Hercules, CA,
42
43 USA). Standard curves using four 10-fold dilutions (1x, 0.1x, 0.01x, 0.001x) were produced to
44
45 ensure that the amplification efficiencies were similar and in the range of 95-105%. The
46
47 mRNA level of each target gene was normalized to the relative amount of the housekeeping
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 gene TBP. The comparative threshold cycles (C_T) method, $2^{-\Delta CT}$, was used to calculate the
5
6 changes in gene expression for each target gene.
7
8
9

10 11 12 ***XBP-1 mRNA splicing*** 13

14
15 Total RNA from HepG2 cells was extracted using the NucleoSpin RNA II Kit (Macherey-
16
17 Nagel, Düren, Germany) following the manufacturer's instructions. The concentration of
18
19 isolated RNA was measured using a NanoDrop ND1000 spectrophotometer. Constant amounts
20
21 of 500 ng of total RNA were reversely transcribed as described for qPCR. The PCR was
22
23 performed using Platinum Taq polymerase under the following conditions: 95°C for 5 min,
24
25 followed by 35 cycles of 50 sec 95°C, 50 sec 50°C and 30 sec at 72°C. The last step was
26
27 incubation at 72°C for 10 min. The XBP-1 primers (forward:
28
29 CCTTGTTAGTTGAGAACCAGG; reverse: GGGGCTTGGTATATATGTGG) amplify the
30
31 unspliced XBP1 mRNA resulting in a 442 bp band and the spliced form with a band at 416 bp
32
33 on an agarose gel [26].
34
35
36
37
38
39
40
41

42 ***Statistical analysis*** 43

44
45 Each experiment was performed at least three times. Representative data are shown. Statistical
46
47 analysis (One-way ANOVA with Tukey-Kramer Multiple Comparison Test or Paired t test
48
49 (Promoter study in Fig. 1D) were performed with GraphPad InStat version 3.00 software. Error
50
51 probabilities < 0.05 were considered to be significant.
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Results

OSM induces the expression of Grp78 in HepG2 cells.

Withdrawal of glucose or stimulation of HepG2 hepatoma cells with OSM leads to an increase in Grp78 protein levels. For both treatments the effect can be seen after 6 h and Grp78 protein levels continuously increase until 12 and 24 h (Fig. 1A, B). As a control for the activity of OSM the phosphorylation of STAT3 was monitored. To investigate whether other cytokines are also able to induce the expression of Grp78, HepG2 cells were treated with OSM, IL-6, IFN- γ and TNF- α . Thapsigargin and the withdrawal of glucose were used as positive controls for the induction of Grp78 (Fig. 1B). OSM and to a lesser extent also IL-6 are the only tested cytokines that lead to an increase in Grp78 protein levels. Interestingly, the levels of Grp94 were unaffected by IFN- γ treatment in HepG2 cells although it was previously reported to up-regulate Grp94 [27].

OSM treatment also affected Grp78 mRNA levels in HepG2 cells (Fig. 1C): a slight (appr. 1.8-fold), but reproducible increase in Grp78 mRNA can be observed which peaks at 12 h treatment. In contrast, OSM did not change mRNA levels of cytosolic Hsp70 (data not shown). To investigate whether OSM affects the activity of the Grp78 promoter we transfected HepG2 cells with a human Grp78 reporter gene construct (Fig. 1D). OSM treatment increased the luciferase activity about 2.5-fold. Thus, in HepG2 hepatoma cells OSM leads to an up-regulation of Grp78 protein, mRNA and to an increased activity of a reporter gene under the control of the human Grp78 promoter.

OSM-mediated up-regulation of Grp78 protein levels is due to de-novo transcription but not due to regulation of protein stability.

1
2
3
4 To further investigate whether *de-novo* transcription of the Grp78 gene is involved in the
5 induction of Grp78 by OSM we treated HepG2 cells with the transcriptional inhibitor
6 actinomycin D (Fig. 2A and Suppl. Fig. 1). As previously observed, the treatment with OSM or
7 tunicamycin or glucose starvation induces the expression of Grp78 protein. However, this up-
8 regulation was abolished if the cells were treated with actinomycin D. Grp78 protein levels
9 slowly declined over time with a kinetics similar to the one for Grp78 mRNA which was
10 reported to be between 4 and 5.5 h [28, 29]. This indicates that the induction of Grp78 by OSM
11 as well as by glucose starvation and by tunicamycin (Fig. 2A and Suppl. Fig.1) involves gene
12 transcription, thereby corroborating the data of the promoter assay (Fig. 1D).
13
14

15
16
17
18
19
20
21
22
23
24
25
26 A change in protein stability is another possible mechanism leading to an increase of protein
27 levels. Therefore we used cycloheximide, an inhibitor of protein translation, to roughly
28 evaluate the half-life of Grp78 (Fig 2B). We used OSM and tunicamycin to induce the
29 expression of Grp78 and followed the decrease of Grp78 protein levels over time after
30 treatment with cycloheximide. No significant difference was observed between the protein
31 stabilities of Grp78 induced by OSM or by tunicamycin (the protein half-life was estimated to
32 be between 30 and 60 minutes), indicating that OSM does not affect the protein half-life of
33 Grp78.
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 ***OSM-mediated induction of Grp78 is restricted to hepatocytes/hepatoma cells.***

49

50 We then performed OSM stimulations of 8 different cell lines to investigate if OSM induced
51 Grp78 also in other cells. Therefore we treated HepG2, Huh-7 (both hepatoma cell lines),
52 PH5CH8 (primary hepatocyte cells), PC-3, DU-145 (both prostate cancer cell lines), FM55M1
53 (melanoma cell line), MCF-7 (breast cancer cell line), and human embryonic kidney cells
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 (HEK) for 6 h, 12 h or 24 h with OSM (Fig. 3A). The activity of OSM was determined by
5
6 monitoring STAT phosphorylation (suppl. Fig. 2). Interestingly, OSM leads to an increase in
7
8 Grp78 protein levels only in the hepatoma or hepatocyte cell lines HepG2, Huh-7 and PH5CH8
9
10 cells. In the other cell lines the amount of Grp78 is only increased by the treatment with
11
12 tunicamycin (data not shown) but not upon OSM stimulation. Similar to HepG2 cells (Fig. 1C),
13
14 the Grp78 mRNA level is also elevated by OSM in Huh-7 and PH5CH8 cells (around 2-fold
15
16 induction) (Fig. 3B). Taken together, the OSM-mediated upregulation of Grp78 is not a general
17
18 effect but seems to be specific to hepatocytes and hepatoma cells.
19
20
21
22
23
24
25

26 ***OSM does not induce a classical ER stress response that is responsible for the increase of***
27 ***Grp78 protein levels.***
28
29

30
31 The up-regulation of Grp78 expression under stress conditions is known to be mediated by
32
33 pathways of the ER stress response. We tested if OSM can induce such signaling cascades.
34
35 Therefore we analyzed the status of XBP-1 mRNA (Fig. 4A). As shown previously [26], the
36
37 ER stress inducer tunicamycin is able to induce the splicing of XBP-1 mRNA which results in
38
39 a PCR product of 416 bp. For OSM no splicing of XBP-1 mRNA was observed, indicating that
40
41 OSM does not activate the ER stress signaling cascade via IRE1 α /XBP-1.
42
43
44
45

46 Since the expression of Grp78 can be induced via the ER stress pathway PERK/eIF2 α /ATF4,
47
48 we investigated whether OSM activates this pathway. In HepG2 cells we could not observe an
49
50 increase in eIF2 α phosphorylation by OSM (Fig. 4B) compared to an increase upon
51
52 tunicamycin treatment (data not shown). Also in Huh-7 and PH5CH8 cells no induction of
53
54 eIF2 α phosphorylation was observed (data not shown). These data were corroborated by
55
56 studying the status of down-stream molecules of eIF2 α signaling activation: The mRNA level
57
58
59
60
61
62
63
64
65

1
2
3
4 of the transcription factor ATF4 and its target gene CHOP remained unaffected by OSM
5
6 treatment whereas tunicamycin induces a significant increase (Fig. 4C).
7

8
9 Taken together, the absence of eIF2 α phosphorylation, XBP-1 mRNA splicing and Grp94 up-
10
11 regulation (Fig. 1B) indicates that the up-regulation of Grp78 by OSM is a rather selective
12
13 process and does not seem to be associated to a general ER stress response.
14
15
16
17
18

19 ***Investigation of the involvement of Jaks, Erk1/2, HIF-1 α and STAT3 in the OSM-mediated***
20
21 ***up-regulation of Grp78.***
22

23
24 OSM is known to induce the Jak1/STAT3, the MAP kinase pathway (Erk1/2 and p38) and is
25
26 an inducer of HIF-1 α [30]. We have recently reported that OSM can induce the expression of
27
28 transcriptionally active HIF-1 α and thus we wondered whether HIF-1 α might contribute to
29
30 OSM-mediated up-regulation of Grp78, as hypoxia is known to lead to ER stress. Therefore,
31
32 we generated HepG2 cells stably expressing shRNA directed against HIF-1 α . Compared to
33
34 “scrambled” control transfectants, OSM only marginally induces HIF-1 α in these cells (Fig.
35
36 5A, left panel). However, OSM-induced Grp78 levels are not affected by HIF-1 α suppression,
37
38 indicating that HIF-1 α is not involved in the up-regulation of Grp78.
39
40
41
42
43

44 To study the implication of STAT3 in the induction of Grp78 by OSM, stable HepG2 cells
45
46 were generated in which STAT3 levels were suppressed by a shRNA plasmid targeting
47
48 STAT3. OSM-induced expression of γ -fibrinogen, a known STAT3-dependent acute phase
49
50 protein, was totally abrogated in these cells (Fig. 5A, right panel). In contrast, the STAT3
51
52 knock-down cells express similar levels of Grp78 as the control cells. It should be noted,
53
54 however, that these stable cells responded to OSM-treatment with stronger signals for P-
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 STAT1, P-STAT5, P-Erk1/2 and P-p38 (suppl. Fig. 3), so the data have to be viewed with
5
6 caution.

7
8
9 This is why we also took advantage of known pharmacological inhibitors targeting Janus
10 kinases and MEK1 (the upstream kinase of Erk1/2) to investigate Grp78 induction by OSM.
11
12 The MEK1 inhibitor U0126 has been shown to specifically inhibit the Erk1/2 activation upon
13
14 OSM (without affecting STAT3 activation) while Jak inhibitor 1 suppresses all signaling
15
16 pathways activated by OSM [30]. Interestingly, the treatment of HepG2 cells with U0126
17
18 decreases the induction of Grp78 (Fig 5B). This finding could be confirmed in Huh-7 and
19
20 PH5CH8 cells (data not shown). The treatment with Jak Inhibitor I showed that OSM-induced
21
22 Grp78 expression crucially depends on Jak activity. The inhibition of OSM-induced Grp78 up-
23
24 regulation with Jak inhibitor 1 was only slightly more efficient compared to the one with the
25
26 MEK1 inhibitor U0126, which is an indication that Erk1/2 activation is the most important
27
28 factor and that STAT3 is involved to a lesser degree.

29
30
31 To corroborate the involvement of Erk1/2 we also performed reporter gene experiments using
32
33 the Grp78 promoter construct (Fig. 5C). The luciferase activity of cells pretreated with U0126
34
35 prior OSM stimulation is reduced almost totally compared to the cells only treated with OSM.
36
37 The residual activity is again indicative of a slight involvement of STAT3, an incomplete
38
39 inhibition of the MEKs, and/or the involvement of additional signaling pathways. Moreover,
40
41 the induction of the Grp78 promoter activity is weaker for IL-6 than for OSM, which is in line
42
43 with our observation in Fig. 1B. We could confirm these results on the mRNA level (Fig. 5D).
44
45 The OSM induced increase of Grp78 mRNA is diminished in presence of Jak inhibitor 1 as
46
47 well as U0126.
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 Taken together, our data point at a major involvement of the Jak-activated MEK/Erk pathway
5
6 in OSM-mediated Grp78 up-regulation, with a minor involvement of STAT3 while OSM-
7
8 induced HIF-1 α is dispensable. We cannot, however, exclude the possibility that other
9
10 signaling pathways are also involved in this regulation.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Discussion

The key findings of the present manuscript are: (1) OSM leads to the selective up-regulation of the ER chaperone Grp78/BiP, which was not mediated by IFN- γ or TNF- α . (2) This up-regulation seems to be specific to liver cells, and does not occur in prostate, melanoma, breast or kidney cells. (3) Grp78 is up-regulated by transcriptional processes which are (4) mostly dependent on MEK/Erk activity, although other pathways may also be involved.

We could show Grp78 up-regulation by OSM to be stronger than by IL-6 and the up-regulation was corroborated in a number of hepatic cell lines. None of the other tested cytokines (IFN- γ or TNF- α) up-regulated Grp78. OSM is known to activate many signaling pathways. The cytokine receptor-bound Janus kinases (Jaks) are the first intracellular relay station of a cytokine signal [31]. Upon cytokine receptor binding the Jaks get activated, transphosphorylate and subsequently phosphorylate tyrosine residues in the cytokine receptor intracellular part, to which SH2 domain-containing signaling proteins can now bind and mediate further signal transduction. Not surprisingly, our studies with the pan-Jak inhibitor JakI1 (Fig. 5B-D) clearly show that Jak activity is crucial for the OSM-mediated effect on Grp78 expression.

Whilst our data obtained with the STAT3-shRNA cells pointed at an only minor role for STAT3 we had to be cautious since in these cells STAT3 suppression was correlated with a stronger activation of other signaling pathways (e.g. STAT1, STAT5, MAPKs), possibly due to the lack of STAT3-induced SOCS3 feedback regulation, as observed before for STAT3 MEFs [32]. However, as STAT1 activation by IFN- γ was not associated with Grp78 up-regulation (see Fig. 1), it is unlikely that the increased Grp78 expression in these cells is mediated by the compensatory stronger STAT1 response. Experiments with pharmacological inhibitors against

1
2
3
4 Janus kinases and MEK-1/2 (the kinases upstream of Erk1/2) showed that Erk1/2 are of crucial
5 importance for Grp78 up-regulation upon OSM and that if STAT3 is involved it only plays a
6
7 minor role. MEK inhibitors abrogated most of the Grp78 mRNA and protein up-regulation
8
9 seen after OSM treatment (Fig. 5B,D) and had deleterious effect in promoter studies (Fig. 5C).
10
11 Preliminary evidence derived from experiments with siRNA directed against Erk1 and/or Erk2
12
13 implies involvement particularly of Erk1 (data not shown).
14
15
16
17

18 Hypoxia has been known to affect the ER stress response, including Grp78 expression [25, 33].
19
20 In addition, we have recently shown that OSM leads to up-regulation of HIF-1 α in hepatoma
21
22 cells and hepatocytes even under normoxic conditions [30]. Therefore we tested whether OSM-
23
24 mediated Grp78 up-regulation could be mediated by HIF-1 α . However, and similar to Song et
25
26 al. [25], we did not find evidence for an involvement of HIF-1 α in the regulation of Grp78/BiP
27
28 expression: Grp78 was readily induced in HepG2 transfectants in which expression of HIF-1 α
29
30 was stably suppressed by shRNA (Fig. 5A).
31
32
33
34
35

36 The fact that we find an involvement of the MEK/Erk pathway in OSM-mediated Grp78
37
38 induction fits well to data obtained in very different systems. Grp78 up-regulation in gastric
39
40 cancer cells upon thapsigargin- and tunicamycin treatment [34] or upon chronic hypoxia
41
42 treatment also depended on MEK/Erk activity [25]. OSM is a stronger inducer of Grp78
43
44 compared to IL-6, although both types of cytokines belong to the family of IL-6-type cytokines
45
46 and both are known to induce the expression of acute phase genes. OSM however has been
47
48 described to lead to a stronger activation of MAP Kinases (e.g. Erk1/2 and p38) than IL-6. This
49
50 has been explained by the fact that the OSM receptor can induce the MAP kinase cascade via
51
52 the SHP2 and Shc adaptor proteins, while IL-6 uses only SHP2 [35]. The fact that Erk1/2
53
54 activation is involved in Grp78 activation may also explain that IL-6 induces less Grp78
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 although it induces a STAT3 response of comparable strength as OSM (see Fig .1B). However,
5
6 further studies are needed to address the potential contribution of other signaling pathways.
7

8
9 We only observed an OSM-dependent up-regulation of Grp78 in liver-derived cells: in
10
11 hepatoma cells (HepG2, Huh-7) and in non transformed hepatocytes (PH5CH8), but not in any
12
13 other cell type investigated so far (Fig. 3). The reason for this cell-type specific up-regulation is
14
15 currently unknown. For cytokine-driven expression of hepatic acute phase response genes
16
17 complex formation of c-Fos, STAT3 and the liver-enriched transcription factor HNF-1 has
18
19 been reported to be essential [36-38]. Thus, it is well conceivable that liver-specific
20
21 transcription factors also collaborate with OSM-induced transcription factors to regulate Grp78
22
23 gene expression. Moreover, OSM might modulate the DNA binding activity or transactivation
24
25 potential of liver-specific transcription factors, as described for HNF-4 upon combined
26
27 treatment with IL-6, IL-1, and TNF [39].
28
29
30
31
32

33
34 Increased Grp78 expression helps cells to better cope with ER stress. Thus, OSM as an
35
36 inflammatory cytokine likely acts on hepatocytes in a way that helps them to be protected
37
38 under inflammatory conditions characterized by microenvironmental stress such as hypoxia.
39
40 OSM is a known inducer of the acute phase response, characterized by the massive production
41
42 of proteins in the ER of hepatocytes to be secreted into the serum such as γ -fibrinogen, α 1-
43
44 antichymotrypsin, and haptoglobin [22]. We discarded the possibility that Grp78 expression is
45
46 simply a “byproduct” of an ongoing acute phase response (and an associated ER stress
47
48 response) for the following reasons: (1) Grp78 up-regulation upon OSM treatment seems to be
49
50 selective, as other characteristics associated to an ER stress response were not observed (XBP-
51
52 1 mRNA splicing, increased levels of eIF2 α phosphorylation, increased Grp94 expression,
53
54 induction of ATF4 and CHOP mRNA (Fig. 4), increased ATF6 cleavage (data not shown)). Of
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 note, in preliminary studies an up-regulation of (unspliced) XBP-1 mRNA could be observed
5
6 upon OSM stimulation (see also Fig. 4A). (2) Grp78 was also up-regulated in HepG2
7
8 hepatoma cells stably expressing a shRNA targeting STAT3 thereby precluding the acute
9
10 phase response as exemplified by the lack of up-regulation of γ -fibrinogen (Fig. 5A).
11
12

13
14 Due to poor vascularization, the tumor microenvironment also promotes the development of
15
16 ER stress in response to nutrient starvation (e.g. glucose) and hypoxia. One characteristic of the
17
18 ER stress response is the induced expression of ER chaperones to increase the folding capacity
19
20 of the ER. Hypoxia and ER stress in human cancer have been associated with the up-regulation
21
22 of chaperones, including Grp78 [33, 40]. It is known that Grp78 is widely expressed in cancer
23
24 cells and seems to favor tumor development, proliferation and survival of cancer cells and
25
26 tumor angiogenesis [17, 41, 42]. Moreover, Grp78 also protects tumor cells against therapy as
27
28 it promotes their resistance to various chemotherapeutic agents [17].
29
30
31

32
33 Also in the liver, Grp78 and the ER stress response seems to be pro-oncogenic: The ER stress
34
35 response has been implicated in hepatocarcinogenesis [43] and in resistance of hepatocellular
36
37 carcinoma cells against drugs such as camptothecin, etoposide and doxorubicin [44, 45]. Since
38
39 a few years, Sorafenib has been successfully applied in the treatment of patients with advanced
40
41 HCC [46, 47]. Sorafenib is a multi-kinase inhibitor but is also known to induce apoptosis with
42
43 the involvement of an ER stress response [48]. Interestingly, Grp78 expression negatively
44
45 correlated in two hepatoma cell lines with responsiveness to Sorafenib treatment: those cells
46
47 expressing higher levels of Grp78 were more resistant to Sorafenib-induced apoptosis [49].
48
49
50

51
52 Inflammation is discussed to favor carcinogenesis and the inflammatory cytokine OSM not
53
54 only leads to an upregulation of HIF-1 α [30] but also of Grp78 as shown in the present study.
55
56
57

58 Both proteins protect cells under conditions of microenvironmental stress, as present under
59
60
61

1
2
3
4 conditions of inflammation and within a tumor. It will be interesting to find out whether a
5
6 selective upregulation of Grp78 by the inflammatory cytokine OSM could favor tumor
7
8 development and resistance against chemotherapeutic drugs. It is possible that the OSM
9
10 signaling pathway may represent an additional target in a co-treatment strategy that could
11
12 increase the efficacy of Sorafenib treatment in HCC patients. Since Grp78 promotes resistance
13
14 of tumor cells to various chemotherapeutic agents, gaining knowledge about the factors and
15
16 mechanisms leading to the enhancement of Grp78 expression is of importance in order to
17
18 improve current cancer treatments.
19
20
21
22
23
24

25 26 Acknowledgements:

27
28 We thank Dr. Kyoungsook Park (Sungkyunkwan University, Korea) for the Grp78 promotor
29
30 construct and Dr. Nobuyuki Kato (Okayama University, Japan) for the PH5CH8 cells. We
31
32 thank Demetra Philippidou for excellent technical help with qPCR.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure legends:**Figure 1: OSM up-regulates Grp78 at the transcriptional and protein level.**

(A) HepG2 cells were treated for the indicated periods of time with OSM (10 ng/mL) or cultured in glucose-free medium (-Glc). Lysates of the cells were separated by SDS-PAGE, and Western blots of the membranes were detected with Grp78, phospho-STAT3, STAT3 and FIN-13 antibodies. Protein levels were quantified by using ImageJ software, Grp78 levels normalized to FIN-13, *: $P < 0.05$, ***: $P < 0.001$. (B) HepG2 cells were treated for the indicated periods of time with OSM, IL-6, IFN- γ or TNF- α (10 ng/mL each), with thapsigargin (Thap) (1 μ M) or cultured in glucose-free medium (-Glc). Lysates of the cells were separated by SDS-PAGE, and Western blots of the membranes were detected with antibodies directed against Grp78, Grp94, phospho-STAT3, STAT3, phospho-STAT1, P-Erk1/2, Erk1/2, phospho-p38, p38, and FIN-13. (C) HepG2 cells were stimulated for the indicated periods of time with OSM (10 ng/mL). RNA was prepared and Grp78 mRNA levels were analyzed by quantitative PCR. ##: $P < 0.001$, statistically significant difference with respect to untreated control cells. (D) HepG2 cells were transfected with the luciferase reporter gene plasmid pGL3-Grp78-Luc and the β -galactosidase expression vector pCH110. 24 h post-transfection the medium was exchanged and the cells were treated for additional 16 h with OSM (10 ng/mL) before lysates were prepared and the reporter gene activity was measured. ***: $P < 0.001$.

Figure 2: OSM up-regulates Grp78 by transcriptional processes and does not induce a stabilization of Grp78 protein.

1
2
3
4 (A) HepG2 cells were treated for the indicated periods of time with OSM (10 ng/mL) or
5
6 tunicamycin (Tn) (1 μ M) in the presence of DMSO alone or actinomycin D (Act D) (5 μ g/mL).
7
8
9 Western blots of lysates separated by SDS-PAGE were detected with Grp78, phospho-STAT3,
10
11 STAT3 and FIN-13 antibodies (B) HepG2 cells were stimulated for 8 h with tunicamycin (1
12
13 μ M) or OSM (10 ng/mL). Then, cycloheximide (10 μ g/mL) was added for the indicated
14
15 periods of time before lysates were prepared. Western blots were detected with Grp78 and
16
17 FIN-13 antibodies. For the Grp78 detection the Western blots were exposed so that the band
18
19 intensity for all treatments was comparable.
20
21
22
23
24
25

26 ***Figure 3: OSM upregulates Grp78 in liver cells.***

27
28 (A) The various cells were treated with OSM (10 ng/ml) for the indicated periods of time or
29
30 were left untreated. Lysates of the cells were separated by SDS-PAGE, and Western blots were
31
32 detected with Grp78 and FIN-13 antibodies. (B) Huh-7 and PH5CH8 cells were stimulated for
33
34 12 h with OSM (10 ng/mL). RNA was prepared and Grp78 mRNA levels were analyzed by
35
36 quantitative PCR. **: P < 0.01, ***: P < 0.001.
37
38
39
40
41
42
43

44 ***Figure 4: OSM does not induce XBP1 mRNA splicing and eIF2 α phosphorylation.***

45
46 (A) HepG2 cells were treated with OSM (10 ng/mL) or tunicamycin (Tn) (1 μ M) for the
47
48 indicated periods of time. RNA was prepared and the spliced and unspliced levels of XBP-1
49
50 were analyzed by semi-quantitative PCR. (B) HepG2 cells were treated with Oncostatin M (10
51
52 ng/mL) for the indicated periods of time. Lysates of the cells were separated by SDS-PAGE,
53
54 and Western blots were detected with Grp78, phospho-STAT3, STAT3, phospho-eIF2 α , eIF2 α
55
56 and FIN-13 antibodies. (C) HepG2 cells were treated with OSM (10 ng/mL) or tunicamycin
57
58
59
60
61
62
63
64
65

1
2
3
4 (Tn) (1 μ M) for 12 h. RNA was prepared and ATF6 and CHOP mRNA levels were determined
5
6
7 by quantitative PCR. ##: $P < 0.001$, statistically significant difference with respect to untreated
8
9 control cells.

10
11
12
13
14 **Figure 5: Jak and Erk1/2 activation plays a role in OSM-induced Grp78 expression in liver**
15
16
17 **cells.**

18
19 (A) HepG2 cells stably expressing either a scrambled RNA control plasmid, a shRNA plasmid
20
21 targeting HIF-1 α or a shRNA plasmid targeting STAT3 were stimulated with OSM (10
22
23 ng/mL) for the indicated periods of time. Lysates of the cells were separated by SDS-PAGE,
24
25 and Western blots of the membranes were detected with HIF-1 α , Grp78, phospho-STAT3,
26
27 STAT3, γ -fibrinogen and FIN-13 antibodies as indicated. (B) HepG2 cells were cultured in
28
29 FCS-free medium overnight. Right panel: cells were pretreated for 30 min with DMSO alone,
30
31 U0126 (2.5 μ M) or Jak inhibitor I (1 μ M). Cells were then stimulated for 9 h with OSM (10
32
33 ng/mL). Left panel: after a 30 min pretreatment with U0126 (5 μ M) or DMSO alone, cells
34
35 were treated with OSM for 3, 6, 9 or 12 h. The lysates were used to prepare Western blots
36
37 which were detected with antibodies directed against Grp78, phospho-STAT3, STAT3,
38
39 phospho-Erk1/2, Erk1/2, and FIN-13. (C) HepG2 cells were transfected with the luciferase
40
41 reporter gene plasmids pGL3-Grp78-Luc and the β -galactosidase expression vector pCH110.
42
43 24 h post-transfection the medium was exchanged and the cells were pretreated for 30 min with
44
45 DMSO alone or U0126 (2.5 μ M). Afterwards the cells were additionally treated for 16 h with
46
47 OSM or IL-6 (10 ng/mL each) before lysates were prepared and the reporter gene activity was
48
49 measured as described in experimental procedures. ##: $P < 0.001$, statistically significant
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 difference with respect to untreated control cells. ***: $P < 0.001$. (D) HepG2 cells were
5
6 cultured overnight in FCS-free medium. Afterwards the cells were pretreated with either Jak
7
8 inhibitor I (1 μM) or U0126 (5 μM) for 30 min prior to an OSM stimulation (10 ng/mL) for 12
9
10 h. ##: $P < 0.001$, statistically significant difference with respect to untreated control cells. ***:
11
12 $P < 0.001$.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Citations:


- [1] Tanaka M, Miyajima A. Oncostatin M, a multifunctional cytokine. Reviews of physiology, biochemistry and pharmacology 2003;149:39-52.
- [2] Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. The Biochemical journal 2003;374:1-20.
- [3] Böing I, Stross C, Radtke S, Lippok BE, Heinrich PC, Hermanns HM. Oncostatin M-induced activation of stress-activated MAP kinases depends on tyrosine 861 in the OSM receptor and requires Jak1 but not Src kinases. Cellular signalling 2006;18:50-61.
- [4] Vasse M, Pourtau J, Trochon V, Muraine M, Vannier JP, Lu H, et al. Oncostatin M induces angiogenesis in vitro and in vivo. Arteriosclerosis, thrombosis, and vascular biology 1999;19:1835-42.
- [5] Nakamura K, Nonaka H, Saito H, Tanaka M, Miyajima A. Hepatocyte proliferation and tissue remodeling is impaired after liver injury in oncostatin M receptor knockout mice. Hepatology 2004;39:635-44.
- [6] Hamada T, Sato A, Hirano T, Yamamoto T, Son G, Onodera M, et al. Oncostatin M gene therapy attenuates liver damage induced by dimethylnitrosamine in rats. Am J Pathol 2007;171:872-81.
- [7] Shiu RP, Pouyssegur J, Pastan I. Glucose depletion accounts for the induction of two transformation-sensitive membrane proteins in Rous sarcoma virus-transformed chick embryo fibroblasts. Proceedings of the National Academy of Sciences of the United States of America 1977;74:3840-4.
- [8] Haas I, Wabl M. Immunoglobulin heavy chain binding protein. Nature 1983;306:387-9.
- [9] Dugaard M, Rohde M, Jaattela M. The heat shock protein 70 family: Highly homologous proteins with overlapping and distinct functions. FEBS Lett 2007;581:3702-10.
- [10] Ni M, Zhou H, Wey S, Baumeister P, Lee AS. Regulation of PERK Signaling and Leukemic Cell Survival by a Novel Cytosolic Isoform of the UPR Regulator GRP78/BiP. PLoS ONE 2009;4:e6868.
- [11] Panayi GS, Corrigan VM. BiP regulates autoimmune inflammation and tissue damage. Autoimmunity reviews 2006;5:140-2.
- [12] Zhang Y, Liu R, Ni M, Gill P, Lee AS. Cell surface relocation of the endoplasmic reticulum chaperone and unfolded protein response regulator GRP78/BiP. The Journal of biological chemistry; in press.
- [13] Dudek J, Benedix J, Cappel S, Greiner M, Jalal C, Müller L, et al. Functions and pathologies of BiP and its interaction partners. Cellular and Molecular Life Sciences 2009;66:1556-69.
- [14] Ni M, Lee AS. ER chaperones in mammalian development and human diseases. FEBS Lett 2007;581:3641-51.
- [15] Li WW, Alexandre S, Cao X, Lee AS. Transactivation of the grp78 promoter by Ca²⁺ depletion. A comparative analysis with A23187 and the endoplasmic reticulum Ca(2+)-ATPase inhibitor thapsigargin. The Journal of biological chemistry 1993;268:12003-9.

- 1
2
3
4 [16] Olden K, Pratt RM, Jaworski C, Yamada KM. Evidence for role of glycoprotein
5 carbohydrates in membrane transport: specific inhibition by tunicamycin. Proceedings
6 of the National Academy of Sciences of the United States of America 1979;76:791-5.
7
8 [17] Lee AS. GRP78 induction in cancer: therapeutic and prognostic implications. Cancer
9 research 2007;67:3496-9.
10
11 [18] Rebouissou S, Amessou M, Couchy G, Poussin K, Imbeaud S, Pilati C, et al. Frequent
12 in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours.
13 Nature 2009;457:200-4.
14
15 [19] Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, et al. Gender
16 disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production.
17 Science (New York, NY 2007;317:121-4.
18
19 [20] Chen D-c, Kawakami M, He J, Sakamoto T, Okada Y. Up-Regulation of Glucose
20 Regulated Protein 78 after Burn Injury. Nihon Kyukyu Igakukai Zasshi 1999;10:623 -
21 4.
22
23 [21] Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response.
24 Biochemical Journal 1990;265:621.
25
26 [22] Richards CD, Brown TJ, Shoyab M, Baumann H, Gauldie J. Recombinant oncostatin M
27 stimulates the production of acute phase proteins in HepG2 cells and rat primary
28 hepatocytes in vitro. J Immunol 1992;148:1731-6.
29
30 [23] Ikeda M, Sugiyama K, Tanaka T, Tanaka K, Sekihara H, Shimotohno K, et al.
31 Lactoferrin markedly inhibits hepatitis C virus infection in cultured human hepatocytes.
32 Biochemical and biophysical research communications 1998;245:549-53.
33
34 [24] Haan C, Behrmann I. A cost effective non-commercial ECL-solution for Western blot
35 detections yielding strong signals and low background. J Immunol Methods
36 2007;318:11-9.
37
38 [25] Song MS, Park YK, Lee JH, Park K. Induction of glucose-regulated protein 78 by
39 chronic hypoxia in human gastric tumor cells through a protein kinase C-
40 epsilon/ERK/AP-1 signaling cascade. Cancer research 2001;61:8322-30.
41
42 [26] Tardif KD. Hepatitis C Virus Suppresses the IRE1-XBP1 Pathway of the Unfolded
43 Protein Response. Journal of Biological Chemistry 2004;279:17158-64.
44
45 [27] Chen YG, Ashok BT, Liu X, Garikapaty VP, Mittelman A, Tiwari RK. Induction of
46 heat shock protein gp96 by immune cytokines. Cell stress & chaperones 2003;8:242-8.
47
48 [28] Bobrovnikova-Marjon EV, Marjon PL, Barbash O, Vander Jagt DL, Abcouwer SF.
49 Expression of angiogenic factors vascular endothelial growth factor and interleukin-
50 8/CXCL8 is highly responsive to ambient glutamine availability: role of nuclear factor-
51 kappaB and activating protein-1. Cancer research 2004;64:4858-69.
52
53 [29] Stein I, Neeman M, Shweiki D, Itin A, Keshet E. Stabilization of vascular endothelial
54 growth factor mRNA by hypoxia and hypoglycemia and coregulation with other
55 ischemia-induced genes. Molecular and cellular biology 1995;15:5363-8.
56
57 [30] Vollmer S, Kappler V, Kaczor J, Flugel D, Rolvering C, Kato N, et al. Hypoxia-
58 inducible factor 1alpha is up-regulated by oncostatin M and participates in oncostatin
59 M signaling. Hepatology 2009; 50:253-60.
60
61 [31] Haan C, Kreis S, Margue C, Behrmann I. Jaks and cytokine receptors--an intimate
62 relationship. Biochemical pharmacology 2006;72:1538-46.
63
64
65

- 1
2
3
4 [32] Costa-Pereira AP, Tininini S, Strobl B, Alonzi T, Schlaak JF, Is'harc H, et al.
5 Mutational switch of an IL-6 response to an interferon-gamma-like response.
6 Proceedings of the National Academy of Sciences of the United States of America
7 2002;99:8043-7.
8
9 [33] Feldman DE, Chauhan V, Koong AC. The unfolded protein response: a novel
10 component of the hypoxic stress response in tumors. *Mol Cancer Res* 2005;3:597-605.
11 [34] Zhang LJ, Chen S, Wu P, Hu CS, Thorne RF, Luo CM, et al. Inhibition of MEK blocks
12 GRP78 up-regulation and enhances apoptosis induced by ER stress in gastric cancer
13 cells. *Cancer letters* 2009;274:40-6.
14 [35] Hermanns HM. Non-redundant Signal Transduction of Interleukin-6-type Cytokines.
15 The adapter protein Shc is specifically recruited to the oncostatin m receptor. *Journal*
16 *of Biological Chemistry* 2000;275:40742-8.
17 [36] Nishikawa T, Hagihara K, Serada S, Isobe T, Matsumura A, Song J, et al.
18 Transcriptional complex formation of c-Fos, STAT3, and hepatocyte NF-1 alpha is
19 essential for cytokine-driven C-reactive protein gene expression. *J Immunol*
20 2008;180:3492-501.
21 [37] Leu JI, Crissey MA, Leu JP, Ciliberto G, Taub R. Interleukin-6-induced STAT3 and
22 AP-1 amplify hepatocyte nuclear factor 1-mediated transactivation of hepatic genes, an
23 adaptive response to liver injury. *Molecular and cellular biology* 2001;21:414-24.
24 [38] Jain S, Li Y, Patil S, Kumar A. HNF-1alpha plays an important role in IL-6-induced
25 expression of the human angiotensinogen gene. *Am J Physiol Cell Physiol*
26 2007;293:C401-10.
27 [39] Wang Z, Burke PA. Effects of hepatocyte nuclear factor-4alpha on the regulation of the
28 hepatic acute phase response. *Journal of molecular biology* 2007;371:323-35.
29 [40] Healy SJ, Gorman AM, Mousavi-Shafaei P, Gupta S, Samali A. Targeting the
30 endoplasmic reticulum-stress response as an anticancer strategy. *Eur J Pharmacol*
31 2009;625:234-46.
32 [41] Dong D, Ni M, Li J, Xiong S, Ye W, Virrey JJ, et al. Critical role of the stress
33 chaperone GRP78/BiP in tumor proliferation, survival, and tumor angiogenesis in
34 transgene-induced mammary tumor development. *Cancer research* 2008;68:498-505.
35 [42] Fu Y, Wey S, Wang M, Ye R, Liao CP, Roy-Burman P, et al. Pten null prostate
36 tumorigenesis and AKT activation are blocked by targeted knockout of ER chaperone
37 GRP78/BiP in prostate epithelium. *Proceedings of the National Academy of Sciences*
38 *of the United States of America* 2008;105:19444-9.
39 [43] Shuda M, Kondoh N, Imazeki N, Tanaka K, Okada T, Mori K, et al. Activation of the
40 ATF6, XBP1 and grp78 genes in human hepatocellular carcinoma: a possible
41 involvement of the ER stress pathway in hepatocarcinogenesis. *J Hepatol* 2003;38:605-
42 14.
43 [44] Al-Rawashdeh FY, Scriven P, Cameron IC, Vergani PV, Wyld L. Unfolded protein
44 response activation contributes to chemoresistance in hepatocellular carcinoma. *Eur J*
45 *Gastroenterol Hepatol*.
46 [45] Hsu JL, Chiang PC, Guh JH. Tunicamycin induces resistance to camptothecin and
47 etoposide in human hepatocellular carcinoma cells: role of cell-cycle arrest and GRP78.
48 *Naunyn-Schmiedeberg's archives of pharmacology* 2009;380:373-82.
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1
2
3
4 [46] Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in
5 advanced hepatocellular carcinoma. *The New England journal of medicine*
6 2008;359:378-90.
7
8 [47] Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular
9 carcinoma. *Drugs* 2009;69:223-40.
10 [48] Rahmani M, Davis EM, Crabtree TR, Habibi JR, Nguyen TK, Dent P, et al. The kinase
11 inhibitor sorafenib induces cell death through a process involving induction of
12 endoplasmic reticulum stress. *Molecular and cellular biology* 2007;27:5499-513.
13
14 [49] Chiou JF, Tai CJ, Huang MT, Wei PL, Wang YH, An J, et al. Glucose-regulated
15 protein 78 is a novel contributor to acquisition of resistance to sorafenib in
16 hepatocellular carcinoma. *Annals of surgical oncology* 17:603-12.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Vollmer *et al.*, (Grp-78)
graphical abstract



All Figures
Figure 1:








Figure 2:








Figure 3:

A



B







Figure 4:

A



B



C






Figure 5:


A




B



C




D



Supplemental information:


Supplemental figure 1: Up-regulation of Grp78 by glucose starvation also involves transcriptional processes (see Fig. 2A, main document, for OSM and tunicamycin treatment).

HepG2 cells were cultured in glucose-free medium (-Glc) for the indicated periods of time in the presence of DMSO alone or actinomycin D (Act D) (5 μ g/mL). Western blots of lysates separated by SDS-PAGE were detected with Grp78, phospho-STAT3, STAT3 and FIN-13 antibodies.



Supplemental figure 3: Dramatic change of the signaling characteristics of OSM upon shRNA-mediated knock-down of STAT3, likely due to the specific suppression of the STAT3/SOCS3 feedback loop.

To study the implication of STAT3 and HIF1 α in the induction of Grp78 by OSM, we generated stable HepG2 cells in which STAT3 or HIF1 α levels were suppressed by a shRNA plasmids targeting the respective proteins. The cells were stimulated with OSM for the indicated periods of time and Western blots of lysates were subjected to detections with antibodies against Grp78, phospho-STAT3, STAT3, phospho-STAT1, STAT1, phospho-STAT5, STAT5, phospho-Erk1/2, Erk1/2, phospho-p38, p38 and FIN-13.



Supplemental results (see also suppl. Fig. 3)

OSM-induced expression of γ -fibrinogen, a known STAT3-dependent acute phase protein, was totally abrogated in STAT3 knock-down cells (Fig. 5A, right panel). In contrast, these cells express similar levels of Grp78 as the control cells. However, upon OSM stimulation these stable cells also responded with stronger and prolonged signals for P-STAT1, P-STAT5, P-Erk1/2 and P-p38 (suppl. Fig. 3). The effect of prolonged STAT1 phosphorylation upon IL-6 treatment was observed before in STAT3-deficient MEFs [1]. The observed prolonged and enhanced signaling can be explained by the lack of STAT3-induced SOCS3 feedback regulation, the SOCS3 gene being dependent on STAT3 for its transcription. SOCS3 binds to the gp130 receptor subunit of the OSM receptor complex and competes with its SH2 domain for the same receptor phosphotyrosine mediating also SHP-2 binding and could therefore modulate SHP-2-mediated MAP kinase signaling in this way. Furthermore, SOCS3 can inhibit Janus kinase activity and regulates both STAT and MAP kinase signaling negatively in this way. In STAT3 containing (“normal”) cells this leads to transient activation of STAT1 and STAT5 upon OSM and only STAT3 signaling is significantly activated over longer times. Erk1/2 and p38 signaling decrease to low level activation after a short transient peak and are visibly induced by phosphorylation for several hours. This behavior is shown by the HIF-1 α negative cells, of which the knock-down has no implications on the signaling behavior upon OSM.

However, as STAT1 activation by IFN- γ was not associated with Grp78 up-regulation (see Fig 1B), it is unlikely that the increased Grp78 expression in these cells is mediated by the compensatory stronger STAT1 response. However, the conclusion that STAT3 is not involved in Grp78 transcriptional regulation cannot be readily deduced from our data, since it is known that Grp78 can be up-regulated by activation of MAP kinases [2-4]. The negative effects on Grp78 expression mediated by STAT3 knock-down might be compensated by stronger induction of MAP kinase family kinases. Furthermore, other possible signal transduction pathways, which have not been investigated by us, might be activated in the shRNA-STAT3-cells and mediate the Grp78 induction.

Generally, this shows that data derived from experiments using si- or shRNA (or knock-down approaches in general) have to be viewed with caution. Effects not due to the

function of the protein but due to its interaction with other proteins can also not be distinguished in knock down approaches. In the case of IL-6 type cytokines, knockdown of one pathway (STAT3) leads to a hyperactivation of at least four others (suppl. Fig. 3). It is known already that IL-6 leads in STAT3-deficient MEF cells to the induction of an interferon γ -like response due to the observed prolonged STAT1 activation [1], but the whole scope of the differences has not yet been investigated.

Citations:

- [1] Costa-Pereira AP, Tininini S, Strobl B, Alonzi T, Schlaak JF, Is'harc H, et al. Mutational switch of an IL-6 response to an interferon-gamma-like response. *Proceedings of the National Academy of Sciences of the United States of America* 2002;99:8043-7.
- [2] Luo S, Lee AS. Requirement of the p38 mitogen-activated protein kinase signalling pathway for the induction of the 78 kDa glucose-regulated protein/immunoglobulin heavy-chain binding protein by azetidine stress: activating transcription factor 6 as a target for stress-induced phosphorylation. *The Biochemical journal* 2002;366:787-95.
- [3] Song MS, Park YK, Lee JH, Park K. Induction of glucose-regulated protein 78 by chronic hypoxia in human gastric tumor cells through a protein kinase C-epsilon/ERK/AP-1 signaling cascade. *Cancer research* 2001;61:8322-30.
- [4] Zhang LJ, Chen S, Wu P, Hu CS, Thorne RF, Luo CM, et al. Inhibition of MEK blocks GRP78 up-regulation and enhances apoptosis induced by ER stress in gastric cancer cells. *Cancer letters* 2009;274:40-6.